Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
The study drug is a once-daily, two-week therapy developed by Sage Therapeutics and Biogen for major depressive disorder (MDD) and postpartum depression (PPD).
The company noted it would continue to assess the STAR study’s complete data set before confirming its future plans for clinical development of timrepigene emparvovec.
Please check out the biopharma industry’s COVID-19 stories that are trending for June 15, 2021.
The failure marks a setback in the hunt for means other than vaccines to provide protection against the novel coronavirus and its variants.
Umoja Biopharma, Alentis Therapeutics, RayzeBio and Camp4 Therapeutics are ramping up on series funds.
The new division would benefit from Hahn’s experience and help steer the company’s Preemptive Medicine and Health Security initiative.
A sense of urgency, powerful science, relentless ingenuity, hope and trust drove the development of Pfizer and BioNTech’s mRNA vaccine during the height of the COVID-19 pandemic. As the crisis appears to lessen, Pfizer is preparing for the next pandemic.
Besides providing a sense of hope for children with this devastating disease, this research could offer another clue toward unlocking the mystery behind other forms of ALS.
Brooklyn ImmunoTherapeutics and Novellus have been doing quite a bit of business together lately, including a licensing agreement and co-locating at a research and development center. Now, a potential acquisition can be added to the growing list.
Per the agreement, CRISPR will lead the research and development of the Friedreich’s ataxia program, while Capsida will shepherd the R&D for the ALS effort.
Investigators from the Cleveland Clinic assessed possible relationships between COVID-19 and neuroinflammation and brain microvascular injury – two hallmarks of AD.
Janssen presented the Phase III Glow study for the elderly with CLL or SLL and the overall survival results from the Phase III MAIA study for patients with NDMM.